Carmel, IN – According to filings with the U.S. Securities and Exchange Commission, MBX Biosciences is raising $35,822,237.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kent Hawryluk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MBX Biosciences

MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available. MBX’s leadership team has collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.

To learn more about MBX Biosciences, visit http://www.mbxbio.com/

Contact:
Kent Hawryluk, Chief Executive Officer
317-989-3100
https://www.linkedin.com/in/khawryluk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved